DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5x64bq/fostair_asthma) has announced the addition of the "Fostair (Asthma) - Forecast and Market Analysis to 2023" report to their offering.
Fostair, developed by Chiesi, is an FDC of the ICS beclomethasone dipropionate and the LABA formoterol fumarate. Beclomethasone dipropionate is a prodrug that is metabolized to two active metabolites. The 17-monopropionate metabolite has a 30-fold greater affinity for glucocorticoid receptors than its 21-monopropionate counterpart and inhibits the secretion of mediators involved in asthma. Beclomethasone dipropionate is marketed as a standalone product, Teva's QVAR. Formoterol fumarate is a highly selective LABA. It acts by increasing cAMP, which, in turn, leads to relaxation of the bronchial smooth muscle.
This way, formoterol inhibits the release of mast cell mediators, such as histamine, leukotrienes, and prostaglandin D2, from the human lung. AstraZeneca markets formoterol as a standalone drug under the name of Oxis Turbuhaler. Other companies also market formoterol, one example being Novartis' Foradil.
- Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Fostair including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Fostair for the top five countries from 2013 to 2023.
- Sales information covered for France, Germany, Italy, Spain and the UK.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Fostair (beclomethasone dipropionate/formoterol fumarate)
For more information visit http://www.researchandmarkets.com/research/5x64bq/fostair_asthma